Why choose medmedian technologies? Median Technologies has also a unique capability to provide on-going reads with short turnaround time and is supported by a proprietary technology that reduces assessment variability through edit checks and automation. Consulting/expertise to complement and enhance request for proposals.Why choose median technologies? Median Technologies has also a unique capability to provide on-going reads with short turnaround time and is supported by a proprietary technology that reduces assessment variability through edit checks and automation. For early phase studies: Faster Go/No Go Decisions.How did medial technologies perform in 2020? Median Technologies records a 51 % increase of its 2020 annual revenue (unaudited figures) 2020 full year revenue of €13.5 million, increased by 51 % compared to 2019 (€9 million) As of December 31, 2020, order backlog of €51.7 million, up 35 % compared to December 31, 2019.Why median technologies for phase i and phase ii? For phases I and II, Median Technologies’ flexibility and access to novel imaging criteria, in addition to the standard ones, allows for a better assessment of the molecule and make better informed Go/No Go decisions.
Median Technologies, Inc. is a District Of Columbia For-Profit Corporation filed On January 23, 2017. The company's filing status is listed as Active and its File Number is C00005569144. The Registered Agent on file for this company is Corporation Service Company and is located at 1090 Vermont Ave. Nw, Washington, DC 20005.